Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors
Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208550666633216 |
|---|---|
| author | Haiting Xu Chenghui Wang Bo Xiao |
| author_facet | Haiting Xu Chenghui Wang Bo Xiao |
| author_sort | Haiting Xu |
| collection | DOAJ |
| description | Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod primes plasmacytoid dendritic cells (DCs) to produce type I interferon, thereby sensitizing conventional DCs in tumors to local Toll-like receptor 7 activation. This approach triggers c-Jun-dependent IL-12 production and CCL2-mediated plasmacytoid DC recruitment, enabling localized and systemic tumor suppression. Importantly, the therapy synergizes with PD-1 blockade to prevent recurrence, representing a significant advance in DC-targeted cancer immunotherapy. |
| format | Article |
| id | doaj-art-61002abd475d41c0ab6749f2e8920d7a |
| institution | OA Journals |
| issn | 2639-5274 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | Article |
| series | Research |
| spelling | doaj-art-61002abd475d41c0ab6749f2e8920d7a2025-08-20T02:10:13ZengAmerican Association for the Advancement of Science (AAAS)Research2639-52742025-01-01810.34133/research.0739Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic TumorsHaiting Xu0Chenghui Wang1Bo Xiao2State Key Laboratory of Resource Insects, College of Sericulture, Textile, and Biomass Sciences, Southwest University, Chongqing 400715, China.Department of Laboratory Medicine, Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 611731, China.Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China.Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod primes plasmacytoid dendritic cells (DCs) to produce type I interferon, thereby sensitizing conventional DCs in tumors to local Toll-like receptor 7 activation. This approach triggers c-Jun-dependent IL-12 production and CCL2-mediated plasmacytoid DC recruitment, enabling localized and systemic tumor suppression. Importantly, the therapy synergizes with PD-1 blockade to prevent recurrence, representing a significant advance in DC-targeted cancer immunotherapy.https://spj.science.org/doi/10.34133/research.0739 |
| spellingShingle | Haiting Xu Chenghui Wang Bo Xiao Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors Research |
| title | Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors |
| title_full | Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors |
| title_fullStr | Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors |
| title_full_unstemmed | Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors |
| title_short | Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors |
| title_sort | systemic ifn i synergizes with topical tlr7 8 agonists to suppress metastatic tumors |
| url | https://spj.science.org/doi/10.34133/research.0739 |
| work_keys_str_mv | AT haitingxu systemicifnisynergizeswithtopicaltlr78agoniststosuppressmetastatictumors AT chenghuiwang systemicifnisynergizeswithtopicaltlr78agoniststosuppressmetastatictumors AT boxiao systemicifnisynergizeswithtopicaltlr78agoniststosuppressmetastatictumors |